Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IDP-107 in severe acne vulgaris with nodules
NCT00666900Phase 2Completed
- Sponsor
- Dow Pharmaceutical Sciences
- Start
- Jan 2008
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of clindamycin and tretinoin in acne vulgaris (3 arms), sponsored by Dow Pharmaceutical Sciences. Primary endpoints: Change from baseline in the number of inflammatory lesions at 12 weeks and Improvement from baseline in global severity at 12 weeks. Started Jan 2008; status: completed.
02
Drugs
clindamycintretinoin
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT00666900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00666900.